Trial · NCT01441973
Adverse events532
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 532
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Elotuzumab(E) : 10 mg/kg/Dose | 5 | 16 | |
| other | Anaemia | Blood and lymphatic system disorders | Elotuzumab(E) : 20 mg/kg/Dose | 2 | 15 | |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Elotuzumab(E) : 10 mg/kg/Dose | 2 | 16 | |
| other | Increased tendency to bruise | Blood and lymphatic system disorders | Elotuzumab(E) : 20 mg/kg/Dose | 0 | 15 | |
| other | Neutropenia | Blood and lymphatic system disorders | Elotuzumab(E) : 10 mg/kg/Dose | 2 | 16 | |
| other | Neutropenia | Blood and lymphatic system disorders | Elotuzumab(E) : 20 mg/kg/Dose | 0 | 15 | |
| other | Atrial fibrillation | Cardiac disorders | Elotuzumab(E) : 10 mg/kg/Dose | 2 | 16 | |
| other | Atrial fibrillation | Cardiac disorders | Elotuzumab(E) : 20 mg/kg/Dose | 1 | 15 | |
| other | Cardiac failure congestive | Cardiac disorders | Elotuzumab(E) : 10 mg/kg/Dose | 1 | 16 | |
| other | Cardiac failure congestive | Cardiac disorders | Elotuzumab(E) : 20 mg/kg/Dose | 0 | 15 | |
| other | Coronary artery disease | Cardiac disorders | Elotuzumab(E) : 10 mg/kg/Dose | 1 | 16 | |
| other | Coronary artery disease | Cardiac disorders | Elotuzumab(E) : 20 mg/kg/Dose | 0 | 15 | |
| other | Palpitations | Cardiac disorders | Elotuzumab(E) : 10 mg/kg/Dose | 1 | 16 | |
| other | Palpitations | Cardiac disorders | Elotuzumab(E) : 20 mg/kg/Dose | 1 | 15 | |
| other | Pericardial effusion | Cardiac disorders | Elotuzumab(E) : 10 mg/kg/Dose | 1 | 16 | |
| other | Pericardial effusion | Cardiac disorders | Elotuzumab(E) : 20 mg/kg/Dose | 0 | 15 | |
| other | Tachycardia | Cardiac disorders | Elotuzumab(E) : 10 mg/kg/Dose | 1 | 16 | |
| other | Tachycardia | Cardiac disorders | Elotuzumab(E) : 20 mg/kg/Dose | 1 | 15 | |
| other | Cerumen impaction | Ear and labyrinth disorders | Elotuzumab(E) : 10 mg/kg/Dose | 2 | 16 | |
| other | Cerumen impaction | Ear and labyrinth disorders | Elotuzumab(E) : 20 mg/kg/Dose | 0 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01441973/events